Antifolate agents: a patent review (2010 – 2013)

Bibliography

• Anderson A, Wright D. Antifolate agents: a patent review (2006-2011). Expert Opin Ther Pat 2011;21:1293-308
   PubMed Web of Science ®Google Scholar
• Zhou W, Scocchera E, Wright D, Anderson A. Antifolates as effective antimicrobial agents: new generations of trimethoprim analogs. Med Chem Commun 2013;4:908-15
   Google Scholar
• Assaraf Y. Molecular basis of antifolate resistance. Cancer Metastasis Rev 2007;26:153-81
   PubMed Web of Science ®Google Scholar
• Zhao X, Li H, Lee R. Targeted drug delivery via folate receptors. Expert Opin Drug Deliv 2008;5:309-19
   PubMed Web of Science ®Google Scholar
• Gonen N, Assaraf Y. Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance. Drug Resist Updat 2012;15:183-210
   PubMed Web of Science ®Google Scholar
• Miller L, Ackerman H, Su X, et al. Malaria biology and disease pathogenesis: insights for new treatments. Nat Med 2013;19:156-67
   PubMed Web of Science ®Google Scholar
• Woodford N, Livermore D. Infections caused by Gram-positive bacteria: a review of the global challenge. J Infect 2009;59:S4-16
   PubMed Web of Science ®Google Scholar
• Drew R. Emerging options for treatment of invasive, multi-drug resistant Staphylococcus aureus infections. Pharmacotherapy 2007;27:227-49
   PubMed Web of Science ®Google Scholar
• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30
   PubMed Web of Science ®Google Scholar
• University of Connecticut. Heterocyclic analogs of propargyl-linked inhibitors of dihydrofolate reductase. US20120196859; 2012
   Google Scholar
• Bolstad D, Bolstad E, Frey K, et al. A structure-based approach to the development of potent and selective inhibitors of dihydrofolate reductase from cryptosporidium. J Med Chem 2008;51:6839-52
   PubMed Web of Science ®Google Scholar
• Liu J, Bolstad D, Smith A, et al. Structure-guided development of efficacious antifungal agents targeting Candida glabrata dihydrofolate reductase. Chem Biol 2008;15:990-6
   PubMedGoogle Scholar
• Viswanathan K, Frey K, Scocchera E, et al. Toward new therapeutics for skin and soft tissue infections: propargyl-linked antifolates are potent inhibitors of MRSA and Streptococcus pyogenes. PLoS One 2012;7(2):e29434
   Web of Science ®Google Scholar
• Paulsen J, Viswanathan K, Wright D, et al. Structural analysis of the active sites of dihydrofolate reductase from two species of Candida uncovers ligand-induced conformational changes shared among species. Bioorg Med Chem Lett 2013;23:1279-84
   PubMed Web of Science ®Google Scholar
• Trius Therapeutics. Dihydrofolate reductase inhibitors. US20120136014; 2012
   Google Scholar
• Li X, Hilgers M, Cunningham M, et al. Structure-based design of new DHFR-based antibacterial agents: 7-aryl-2,4-diaminoquinazolines. Bioorg Med Chem Lett 2011;21:5171-6
   PubMed Web of Science ®Google Scholar
• National Science and Technology Development Agency. Anti-folate antimalarials with dual-binding modes and their preparation. WO2012121682; 2012
   Google Scholar
• Nzila A, Rottmann M, Chitnumsub P, et al. Preclinical evaluation of the antifolate QN254, 5-chloro-N'6'-(2,5-dimethoxy-benzyl)-quinazoline-2,4,6-triamine, as an antimalarial drug candidate. Antimicrob Agents Chemother 2010;54:2603-10
   PubMed Web of Science ®Google Scholar
• Yuvaniyama J, Chitnumsub P, Kamchonwongpaisan S, et al. Insights into antifolate resistance from malarial DHFR-TS structures. Nat Struct Biol 2003;10:357-65
   PubMedGoogle Scholar
• Auspex Pharmaceutical, Inc. Diaminoquinazoline inhibitors of dihydrofolate reductase. WO2010068920; 2010
   Google Scholar
• Chelsea Therapeutics, Inc. Enzyme inhibiting compounds. US20110112126; 2011
   Google Scholar
• Chelsea Therapeutics, Inc. Substituted pyrrolo[2,3-d]pyrimidines as antifolates. US20110152276; 2011
   Google Scholar
• Chelsea Therapeutics, Inc. Enzyme inhibiting compounds. WO2011056957; 2011
   Google Scholar
• McGuire J, Haile W. Metabolism-blocked antifolates as potential anti-rheumatoid arthritis agents: 4-amino-4-deoxy-5,8,10-trideazapteroyl-d,l-4'-methyleneglutamic acid (CH-1504) and its analogs. Biochem Pharmacol 2009;77:1161-72
   PubMed Web of Science ®Google Scholar
• Wolf Greenfield & Sacks, P.C. Novel inhibitors of folic acid-dependent enzymes. US20100249141; 2010
   Google Scholar
• University of Greenwich. New medical use of triazine derivatives. US20130005732; 2013
   Google Scholar
• Duquesne University of the Holy Ghost. Tricyclic compounds having cytostatic and/or cytoxic activity and methods of use thereof. US8314114B2; 2012
   Google Scholar
• Gangjee A, Zhao Y, Ihnat M, et al. Novel tricyclic indeno[2,1-d]pyrimidines with dual antiangiogenic and cytotoxic activities as potent antitumor agents. Bioorg Med Chem 2012;20:4217-25
   PubMed Web of Science ®Google Scholar
• University of South Carolina. Structure based design of inhibitors of human thymidylate synthase. US20120077978; 2012
   Google Scholar
• Concert Pharmaceuticals, Inc. Fluorouracil derivatives. WO2011109274; 2011
   Google Scholar
• BTG International Ltd. Anti-cancer cyclopenta(g)quinazoline compounds. US20100273817; 2010
   Google Scholar
• Theti D, Jackman A. The role of alpha-folate receptor-mediated transport in the antitumor activity of antifolate drugs. Clin Cancer Res 2004;10:1080-9
   PubMed Web of Science ®Google Scholar
• Calvert A. Biochemical pharmacology of pemetrexed. Oncology 2004;18:13-27
   PubMedGoogle Scholar
• Young C, Currie V, Balter L, et al. Phase I and clinical pharmacologic study of LY264618, 5,10-dideazatetrahydrofolate. Proc Am Assoc Cancer Res 1990;31:177
   Google Scholar
• Budman D, Johnson R, Barile B, et al. Phase I and pharmacokinetic study of LY309887: a specific inhibitor of purine biosynthesis. Cancer Chemother Pharmacol 2001;47:525-31
   Google Scholar
• Bissett D, McLeod H, Sheedy B, et al. Phase I dose-escalation and pharmacokinetic study of a novel folate analogue AG2034. Br J Cancer 2001;84:308-12
   Google Scholar
• Bronder J, Moran R. Antifolates targeting purine synthesis allow entry of tumor cells into S phase regardless of p53 function. Cancer Res 2002;62:5236-41
   Google Scholar
• Racanelli A, Rothbart S, Heyer C, et al. Therapeutics by cytotoxic metabolite accumulation: pemetrexed causes ZMP accumulation, AMPK activitation and mammalian target of rapamycin inhibition. Cancer Res 2009;69:5467-74
   PubMed Web of Science ®Google Scholar
• Duquesne University of the Holy Ghost. Selective proton coupled folate transporter and folate receptor and garftase and/or other folate metabolizing enzymes inhibitor compounds and methods of using the same. US20110082158; 2011
   Google Scholar